Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Evolution and Platform Validation Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to translating them into tangible clinical evidence and measurable impact. Performance is attributed to an 'end-to-end' integration of AI-driven biology, chemistry, and clinical development, which management believes creates a compounding effect on R&D decision-making. The company is utilizing a 'lab-in-the-loop' strategy to generate high-quality, fit-for-purpose multimodal data, combining proprietary private data with public datasets to ensure unique model insights. Strategic positioning emphasizes 'repeatability' and 'scalability' in drug discovery, aiming to transform the traditionally probabilistic nature of biotech into a more predictable engineering-focused process. Operational efficiency is highlighted by the claim of synthesizing 90% fewer
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead [Seeking Alpha]Seeking Alpha
- Recursion's REC-4881 Milestone And Cash Runway Shift Risk Reward Profile [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RXRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Recursion Pharmaceuticals (RXRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Recursion Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/3/26 - Form 144
- 2/25/26 - Form S-8
- 2/25/26 - Form 424B5
- RXRX's page on the SEC website